546 results about "Vascular stents" patented technology

Light- and/or UV-radiation protective coatings for drug delivery devices, such as, for instance, drug eluting vascular stents, where the drugs being delivered via the stents are light sensitive. A method of fabricating a medical article, such as a drug eluting vascular stent, that includes the light- and/or UV-radiation protective coating.

This invention is directed toward surface treatment of a device. The surface treatment comprises the attachment of terminal functionalized surfactants to the surface of the substrate by means of reactive functionalities of the terminal functionalized surfactant material reacting with complementary surface reactive functionalities in monomeric units along the polymer substrate. The present invention is also directed to a surface modified medical device, examples of which include contact lenses, intraocular lenses, vascular stents, phakic intraocular lenses, aphakic intraocular lenses, corneal implants, catheters, implants, and the like, comprising a surface made by such a method.

It is a general object of the invention to provide a method of effecting repair or replacement or supporting a section of a body tissue. Specifically to provide an elastin or elastin-based biomaterial suitable for use as a stent, for example, a vascular stent, or as conduit replacement, as an artery, vein or a ureter replacement. The biomaterial can also be used as a stent or conduit covering or coating or lining. It is also an object of the invention to provide a method of securing an elastin or elastin-based biomaterial to an existing tissue without the use of sutures or staples.

Methods, compositions and devices for inhibiting restenosis are provided. Specifically, bisphosphonate compositions and medical devices useful for the site specific delivery of bisphosphonates are disclosed. In one embodiment the medical device is a vascular stent coated with a bisphosphonate selected from the group consisting of zolendronate and pamedronate and derivatives and analogues thereof. In another embodiment an injection catheter for delivery an anti-restenotic effective amount of bisphosphonate to the adventitia is provided.

The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.

Reduction of the likelihood of adverse inflammatory reaction to an implant or a transplant is achieved through several mechanisms including the catalysis of isomerization of peroxynitrite by a hydrogel-bound peroxynitrite isomerization catalysts. A second mechanism controls acceptable and unacceptable dimensions of surface features of implants, such as vascular stents. A third mechanism fabricates implants from materials which are substantially free from alloys transition metals which produce ions of which catalyze cell killing radical formation.

An intravascular stent assembly for implantation in a body lumen, such as a coronary artery, is designed to treat a lesion with vulnerable plaque by reducing the fibrous cap stresses. The stent includes distal, proximal, and center sections where the center section is configured to treat the vulnerable plaque. The stent consists of radially expandable cylindrical rings generally aligned on a common longitudinal stent axis and either directly connected or interconnected by one or more interconnecting links placed so that the stent is flexible in the longitudinal direction while providing high degrees of radial strength and vessel scaffolding.

Medical devices and related methods for making and using same suitable for treating or inhibiting restenosis are proved. Specifically, compositions and methods for I kappa B alpha (IkBα)nuclear factor kβ (NFkβ) complex breakdown inhibition are provided. One embodiment includes a CRM-1 protein binding composition such as leptomycin B. Another embodiment includes a combination of a CRM-1 protein binding composition and a nucleic acid encoding for mammalian IkBα. Medical devices disclosed include catheters and vascular stents.

A hydrogel forming system which comprises a hydrophobic macromer with unsaturated group terminated ends and a hydrophilic polymer which is a polysaccharide containing hydroxy groups which are reacted with unsaturated group introducing compound, is convertible by free radical polymerization to form a hydrogel containing a three dimensional crosslinked polymer network containing hydrophobic and hydrophilic components. Agent can be entrapped in the polymer network, e.g., drugs, macromolecules or synthetic or natural polymers, for controlled release therefrom. In one embodiment, a vascular stent is coated with hydrogel with therapeutic agent entrapped therein.

A tubular vascular stent graft with passively pulsating midsection where the difference between the cross-sectional areas of the lumen under the systolic and diastolic pressures after the implantation is 10% or more. The pulsating stent graft accumulates blood during the systolic pressure wave thus lowering the peak value of the tugging force at the proximal attachment site.

The invention discloses a degradable vascular stent with a composite coating and a preparation method thereof, and comprises a matrix made from pure magnesium or magnesium alloy material; a chemical oxide film layer that is arranged on the surface of the matrix and is used for decreasing the corrosion rate of the matrix and prolonging the service life of the matrix; a degradable polymer material layer that is located at the surface of the chemical oxide film layer and therapeutic drug that are fixed at the degradable polymer material layer. The degradable vascular stent with a composite coating of the invention has excellent mechanical and pharmacological properties, otherwise, the degradation rate of the magnesium material is reduced, and the service life of the stent is prolonged.

The invention discloses a branching type aortal vascular stent system comprising an aortal vascular stent and three branch arterial vascular stents, wherein a concave part is formed in the middle section of the aortal vascular stent, and provided with three side holes; and the three branch arterial vascular stents are separately mounted in the three side holes. The branching type aortal vascular stent system is capable of isolating aortal lesion involving the aortic arch and the ascending aorta, reestablishing the blood flow of the branch artery and avoiding the customization of the stent; and the branching type aortal vascular stent system is suitable for batch production and can be used for emergency operations.

The invention discloses a recyclable vascular stent and a recycling method thereof. The vascular stent comprises a tubular netted framework woven by silks, the end part of the stent is provided with a connecting structure, and the connecting structure forms separable connection with a stent conveyor; the stent can be arranged in the stent conveyor, and can be restored to the original shape after being released; and net holes on the part of the connecting structure are more loosen than other grids, and are used for repeatedly positioning and/or recycling the stent in a vascular cavity. The netholes positioned on the connecting structure on the end part of the stent are easier to stretch and deform than other net holes at other positions, the connecting structure is folded and pulled into a sheath catheter of the stent conveyor, and the rest part of the stent is also collected in the sheath catheter of the stent conveyor, so an operator is greatly convenient to adjust the form of the stent and adjust the proper position of the stent in the vascular cavity and even recycle the stent from the vascular cavity, the repeated positioning and smooth recycling of the vascular stent are realized, and the technical requirement of PTA therapy is better met.